A new anti-rejection medicine for kidney transplant patients
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new medication called TNX-1500 that may help prevent the body from rejecting a new kidney. It is given along with standard anti-rejection medicines, and the goal is to see if it can keep your kidney working longer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must be listed for a kidney transplant or have advanced kidney disease (stage IV or V).
- Your kidney donor can be living or deceased, but must have a compatible blood type.
- You must have had Epstein-Barr virus in the past (most adults have).
- You must be willing to practice effective birth control if you can become pregnant.
- You cannot have certain infections (like HIV, hepatitis B, or untreated hepatitis C), recent severe infections, or significant heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medicines (Sip-Tego) to help your body accept a living donor kidney without needing lifelong anti-rejection drugs. It is for people with advanced kidney failure who are getting a first or second transplant.
This trial is testing a new blood test (called TreaT-Assay) to help diagnose acute rejection after a kidney transplant. The goal is to catch rejection earlier and more accurately, so you can get the right treatment faster.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This study looks at whether Envarsus XR helps prevent “subclinical” (not obviously noticeable) kidney transplant rejection by changing blood immune test results. You may be able to join if you recently received a kidney transplant and can take the study medicine as required.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.